Abstract: We identified a novel IRF2BP2 mutation in a family with a member diagnosed with IEI. Immune monitoring and WGS as auxiliary tests are helpful in identifying genetic defects and assisting diagnosis in patients with clinically highly suspected immune abnormalities and deficiencies in inflammation regulation. In addition, mNGS techniques allow a more comprehensive assessment of the pathogenic characteristics of these patients. This report further validates the association of IRF2BP2 deficiency and IEI, and expands IEI phenotypes.
Introduction: The Diagnostic Odyssey of Inborn Errors of Immunity
Inborn Errors of Immunity (IEI) represent a complex group of over 480 genetic disorders where the immune system either fails to provide adequate protection (immunodeficiency) or lacks the necessary regulatory "brakes" (autoimmunity). A significant challenge in clinical immunology is the "diagnostic odyssey." When a patient presents with overlapping symptoms—such as chronic gut inflammation and sudden neurological decline—clinicians must distinguish between persistent infections and primary autoimmune dysregulation. This case report, published in Frontiers in Immunology, explores how modern sequencing can pinpoint a monogenic cause for these symptoms, specifically focusing on the IRF2BP2 gene.
Clinical Journey and Diagnostic Investigations
The patient, a 22-year-old male, experienced a decade-long history of recurrent infections and autoimmune complications, including chronic rhinitis, recurring dental ulcers, and Crohn’s disease. In 2021, his condition escalated to include frequent fever, cognitive impairment, and behavioral changes, eventually diagnosed as autoimmune encephalopathy.
To navigate this complex presentation, researchers employed a multi-omic approach. Metagenomic Next-Generation Sequencing (mNGS) was used to sequence all DNA/RNA in blood, CSF, and intestinal biopsy samples. By finding no pathogenic bacterial, viral, or fungal signatures, the team ruled out active infection, allowing them to safely proceed with intensive immunosuppressive therapy.
Genetic Discovery and Immune Phenotyping
Whole Genome Sequencing (WGS) identified a novel 12-base pair duplication mutation in the IRF2BP2 gene (c.439_450dup; p.Thr147_Pro150dup). This mutation is located near the N-terminal of the protein, a departure from previously reported mutations typically found in the C-terminal RING domain.
Immune profiling revealed a phenotype similar to Common Variable Immunodeficiency (CVID), characterized by slightly low IgG levels, significantly decreased B-cell plasmablasts, and a skewed T-cell population. IRF2BP2 normally acts as a negative regulator of NFAT (nuclear factor of activated T cells). The mutation effectively breaks this "brake," leading to the high levels of inflammatory cytokines (TNF and IL-1β) observed in the patient.
Discussion: Incomplete Penetrance and Clinical Outcomes
An intriguing finding was the presence of the same mutation in the patient's father, who remained largely asymptomatic. This phenomenon, known as incomplete penetrance, suggests that the IRF2BP2 mutation is necessary but not sufficient for disease manifestation; environmental triggers or other genetic modifiers likely play a role.
Based on the diagnosis of primary immune dysregulation, the patient was treated with cyclophosphamide and corticosteroids. This targeted approach led to a steady improvement in both cognitive and physical symptoms, achieving clinical remission by early 2022.
Conclusion and Future Directions
This case highlights the utility of WGS and mNGS in resolving complex clinical presentations of IEI. While the clinical evidence for the pathogenicity of the c.439_450dup mutation is strong, it is currently classified as a Variant of Uncertain Significance (VUS). Future functional studies, such as CRISPR-based cell modeling, are required to definitively prove the mechanism of protein dysfunction. This report expands the known phenotypic spectrum of IRF2BP2 deficiency and underscores the importance of genomic tools in guiding life-saving therapy.
Summary updated